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Abstract Systemic mastocytosis (SM) is a rare chronic mye-
loproliferative neoplasm with only limited epidemiologic data
published so far. We aimed to analyze the clinical and molec-
ular diagnostic features, and the prognosis and cumulative
incidence of SM cases in a cohort of south-eastern
Hungarian patients of 13 year follow up. In the period
2001–2013, 35 consecutive SM cases were diagnosed in our
regional centre. Immunophenotype, KITD816Vmutation fre-
quency and clinical characteristics, and the prognosis impact
of clinical subtypes were tested and compared with published
data. Indolent SM (ISM) was diagnosed in 14 patients, SM
with an associated clonal hematologic non-mast cell lineage
disease (SM-AHNMD) in 15 patients and aggressive SM
(ASM) in 6 patients. The KIT D816V mutation was found in
11/14 (78 %) of the ISM cases, in 12/15 (80 %) of the SM-
AHNMD cases and in 5/6 (83 %) of the ASM cases. The life
expectancy of ISM patients was better, whereas the SM-
AHNMD and ASM groups exhibited a reduced median
survival. The cumulative incidence for 13 year of the SM
was 0.27/10,000. We detected lower 13 year cumulative SM
incidence than of published epidemiologic data due to in our
analyses involved only those patients who had bone marrow
biopsy and histopathologically confirmed SM. This clinical
overview clearly showed that the clinical characteristics differ
between ISM (UP, anaphylaxis and osteoporosis) and SM-
AHNMD/ASM (cytopenia, eosinophilia and splenomegaly).
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Introduction
Systemic mastocytosis (SM) is a rare chronic myeloprolifera-
tive neoplasm characterized by morphologically and
immunophenotypically abnormal mast cell proliferation in
single or multiple extracutaneous organs [1–4]. To date only
limited epidemiologic data have been published; the preva-
lence of SM in Central Europe has been estimated to be 0.5–
1:10,000 [5]. Local regional data have been reported from
Groningen on indolent SM (ISM) [6] and population based
epidemiological data from Denmark [7]. The recently
established centralized ECNM registry currently collects data
from ten European countries, with the aim of comparing the
incidence and biology of this rare disease in the regions and
countries throughout Europe [8].
The 2008World Health Organization (WHO) classification
categorizes SM patients into various subtypes: ISM; SM with
an associated clonal hematologic non-mast cell lineage dis-
ease (SM-AHNMD) for example acute myeloid leukaemia
(AML) or myelodysplastic syndrome (MDS) or chronic
myelomonocytic leukemia (CMML); aggressive SM (ASM);
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mast cell leukaemia (MCL); mast cell sarcoma (MCS); and
extracutaneous mastocytoma. On the basis of the histopatho-
logical findings and organ damage, a definitive variant the
smouldering type of SM (SSM) was also introduced in 2007
[9]. The clinical presentation and prognosis in SM patients
varies from indolent asymptomatic to an aggressive disease
course. The symptoms can vary with the nature of the organ
infiltration (e.g. anaemia, thrombocytopenia, malabsorption,
hepato- and splenomegaly possibly causing a secondary organ
dysfunction) or the mediator-related symptoms, such as
cramps, flushes, diarrhoea or pruritus [10].
The diagnosis of SM is based on the presence ofminor (such
as the abnormal mast cell morphology in bone marrow; the
expression of CD25 and/or CD2 in the abnormal mast cells;
the presence of the KIT D816V mutation; the elevated serum
total tryptase level) and major (the presence of multifocal clus-
ters of morphologically abnormal mast cells in the bone mar-
row) criteria [11, 4]. The KIT D816V gain-of-function muta-
tion, a substitution of aspartate (D) to valine (V) at position 816
in the kinase domain, found on exon 17, can cause
autoactivation of the KIT receptor tyrosine kinase [12, 13].
However, this mutation is not specific for mastocytosis: it has
also been reported in gastrointestinal stromal tumours, acute
myeloid leukaemia and germ cell tumours [9, 14, 15]. Themost
of adult SM cases exhibit this mutation [12, 16].
It has recently been reported that the presence of KIT
D816V may be sufficient to cause ISM but not ASM, though
it is still questionable whether this mutation alone could be
responsible for the diverse clinical presentation of
mastocytosis [17, 11]. Interestingly it has also been
established that the presence of the KIT D816V mutation in
all haematopoietic lineages and the presence of elevated beta2
microglobulin levels are associated with a more aggressive
form of mastocytosis, and might be identified as possible pre-
dictors of the disease progression [18, 19].
The KIT D816V mutation can cause resistance to imatinib
mesylate [17, 20, 18]. In contrast, the wild-type KIT and sev-
eral rare KIT mutations such as F522C and V559G have been
demonstrated to be imatinib-sensitive [21].
The aim of this work was to calculate the 13 year cumula-
tive incidence of the SM in a south-eastern hungarian haema-
tological clinical centre and to survey the immunophenotypes,
the KIT D816V mutation frequency, the clinical characteris-
tics and the life expectancy in each subtype and in each case of
SM cases which diagnosis were established on bone marrow
biopsy in the last 13 years (2001–2013). At the time of this
survey, the centre catered for 1,103,463 inhabitants aged
15 years or more from south-eastern Hungary [22].
Patients and Methods
Patients and Data Collection
Our centre is a regional centre that caters for the population of
three counties in south-eastern Hungary, Southern Great Plain
on map (Fig. 1). Our data originated in part from medical
database of our centre, sorting with the ICD code
(International Classification of Diseases, ICD-10) outpatient
database and the inpatient database, and in part from the bone
marrow biopsy findings assessed by the tumour pathology
laboratory.
C-KITmutation examinations are made on every bonemar-
row biopsy sample evaluated at our centre. Only those cases
are considered to involve SM which comply strictly with the
WHO 2008 criteria (1 major+1 minor or at least 3 minor
criteria together). In Hungary, serum tryptase level measure-
ment is currently still not available, but (even without the
determined tryptase levels) all of our presented cases meet
the WHO criteria of 2008.
Fig. 1 Introduction of the area of
our regional centre in Hungary
that caters for the population of
three counties in south-eastern
Hungary (Southern Great Plain)
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Between 2001 and 2013, 35 patients were diagnosed with
SM (15 females and 20 males with a median age of 57 years,
range: 31–85 years): 14 with ISM, 15 with SM-AHNMD and
6 with ASM subtypes. All the haematological and pathologi-
cal results on these patients were collected from the medical
data files and reviewed with the approval of the Regional and
Institutional Human Medical Biological Research Ethics
Committee. Informed consent was not required. The study
was conducted in accordance with the Declaration of
Helsinki. The haematological management strategy was based
on the current available recommendations at the time of the
patient’s diagnosis, and the therapy initiation [9, 23, 24, 11,
25, 17, 26–28].
Pathology
All bone marrow trephines were routinely fixed in Schaffer’s
fixative, decalcified in 12.5 % (w/v) pH 7.0 EDTA solution,
and embedded into paraffin. Diagnostic immunohistochemi-
cal stains to CD117, CD25, mast cell tryptase, CD68, and
phospho-STAT5 were made following a heat-induced antigen
retrieval.
To detect KIT D816V mutation, polymerase chain reaction
(PCR) was performed on each bone marrow trephine utilizing
an allele-specific method (Schumacher) with modified param-
eters [29]. The results were validated by direct sequencing
using an Applied Biosystems® 3500 DX Series genetic ana-
lyzer [29].
Statistical Analysis
Kaplan-Meier statistical analyses were made to evaluate the
survival probability in the various SM subgroups (ISM, SM-
AHNMD, and ASM) .
For each year we calculated the incidence rate as the number
of new cases divided by the mid-year population size. The latter
was calculated as the mean of the population size on 1st January
on the relevant year and the next year. The cumulative incidence
(CI) for 13 year was calculated as:CI ¼ 1−e−∑13i¼1 IRi⋅ti, where
IRi denotes the yearly incidence rates from the 1
st to the 13th
year, and ti denotes the length of each time period , which is
1 year in this case for all the 13 periods.
Results
The bone marrow biopsies revealed ISM in 14 patients (8
males and 6 females) with a median age of 55 years (range:
31–81 years). The median follow-up time was 50.5 months
(range: 5–240 months). Cutaneous lesions (urticaria
pigmentosa) were detected in 57 % (8/14) of the ISM pa-
tients. Mediator-related symptoms appeared in 28 % (4/14) of
them. TheKITD816Vmutation was detected in 78% (11/14).
The main characteristics are introduced at Tables 1 and 2,
while the detailed data on the clinical symptoms, the
immunophenotypes, PCR and sequencing analysis in each
patient are introduced in Supplementum 1 and 2.
SM-AHNMD was diagnosed in 15 patients (7 males and 8
females) with a median age of 57 years (range: 34–72 years).
The median duration of follow-up was 25 months (range: 1–
104 months). The bone marrow biopsy was indicated in these
cases by the symptoms of the associated neoplasm, such as a
bone lesion, or clinically relevant blood cell count abnormal-
ities, for example eosinophilia or the elevated or decreased
platelet or white blood cell count. This subtype of SM was
associated with myelodysplastic syndrome (MDS) or with
AML in 3 cases each, with myelofibrosis (MF) in 2 cases, or
with ET, PV, chronic myeloid leukaemia (CML),
hypereosinophilic syndrome (HES), multiple myeloma
(MM), peripheral T-cell lymphoma (PTCL) or B-cell acute
lymphoblastic leukaemia (B-ALL) in 1 case each. No cutane-
ous lesions or mediator-related symptoms were detected in
these cases. The KIT D816V mutation was detected in 80 %
(12/15). The detailed data on the individual SM-AHNMD
patients are presented in Supplementum 1 and 2.
ASM was diagnosed in 6 patients (4 males and 2 fe-
males) with a median age of 65 years (range: 54–85 years).
The median follow-up period was 20.5 months (range: 2–
35 months). The indications of bone marrow biopsy in
these cases were hepatosplenomegaly with or without pan-
cytopenia/anaemia/eosinophilia and a weight loss.
According to the WHO criteria at least one or more C
findings (marked cytopenia; osteolysis with or without
pathologic fractures; ascites and elevated liver enzymes;
malabsorption plus hypalbuminaemia , palpable spleno-
megaly with hypersplenism) were present in all of ASM
cases [23, 11]. Cutaneous lesions were observed in 33 %
(2/6) of the patients. Mediator-related symptoms were
present in 1 case. The KIT D816V mutation was detected
in 83 % (5/6) of the patients. The detailed data are to be
seen in Supplementum 1 and 2.
The survival data of each SM subtype according to Kaplan-
Meier survival curve analysis are presented in Fig. 2.
The median survival for the ASM group was 1.73 years,
while that for the SM-AHNMD group did not reach the me-
dian during the observed follow-up period. No patients died
during the follow-up period in the ISM group. The Mantel-
Cox, Breslow and Tarone-Ware tests uniformly led to p=
0.000, demonstrating that the survival differed significantly
in the observed subgroups.
Our regional medical university centre receives SM patients
from among 1,103,463 inhabitants aged 15 years or more in
south-eastern Hungary [22], and this allowed to calculate the
cumulative incidence for 13 year of the of SM in general popu-
lation, which proved to be 0.27/10,000 in this region.
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Four patients (cases 2, 13, 29 and 35) were excluded from
this cumulative incidence estimation: although they were di-
agnosed in our regional centre, they were not inhabitants of
this region of Hungary.
Discussion
The aim of this paper was to summarize our clinical experi-
ence in SM in the period 2001–2013. Since there is no official
national mastocytosis registry in Hungary, we aimed to use
our regional data to calculate the cumulative incidence of SM
in a south-eastern hungarian clinical centre, based on only
those cases (introduced above) which were referred to histo-
pathological analysis of bone marrow biopsy and the presence
of SM were confirmed.
Our analyses demonstrated that the main cause of the
indication of the bone marrow biopsy in the group of ISM
patients was urticaria pigmentosa (8/14; 57 %). It is im-
portant, therefore, that the dermatologist should refer the
patients to haematological centres to establish the poten-
tial bone marrow involvement in the presence of cutane-
ous mastocytosis lesions. In other cases, the bone marrow
biopsy was indicated by eosinophilia (3/14; 21 %), anae-
mia (1/14; 7 %), lytic bone lesions (1/14; 7 %) or
adenomegaly (1/14; 7 %).
Table 1 Main clinical characteristics of the patients
Characteristics ISM SM-AHNMD ASM
Patients (N) 14 15 6
Males (N) 8 7 4
Females (N) 6 8 2
Median age at diagnosis, median (years) (range) 55 (31–81 ) 57 (34–72) 65 (54–85)
Median follow up (months) (range) 50.5 (5–240) 25 (1–104) 20.5 (2–35)
Associated haematological disease none MDS(3);AML(3);MF (2); ET(1); PV(1);CML(1);
iHES(1);MM(1);PTCL(1); B-ALL(1)
none
Urticaria pigmentosa 8/14 none none
Mediator-related symptoms:
skin (S)
gastrointestinal (GI)
cardiovascular (CV)
neurological (N)
anaphylaxis (A)
S: 5/14;
GI: 3/14;
CV: 2/14;
N: 1/14;
A: 2/14
none S: 2/6;
N:1/6
Coexistent allergy
(inhalative, nutritive, drug, insect)
3/14 none none
Constitutional symptoms 2/14 1/15 6/6
Organ damage / organopathy:
Hepatomegaly (H), Splenomegaly (S),
Adenopathy(A),
Osteopenia/
osteoporosis/osteolysis(O)
H: 2/14;
H*: 1/14;
A: 1/14;
O: 3/14
H: 3/15;
S: 2/15;
A: 1/15
H*: 6/6;
S: 3/6;
A: 3/6;
O: 3/6
C findings none none 6/6
Abbreviations: ASM aggressive systemic mastocytosis; ISM Indolent systemic mastocytosis; SM-AHNMD systemic mastocytosis with an associated
clonal hematologic non-mast cell lineage disease;mediator- related symptoms; S skin (flush, pruritus); GI gastrointestinal symptoms (diarrhoea); CV
cardiovascular (palpitation, dizziness, syncope); N neurologic; A anaphylaxis; Constitutional symptoms were observed generalized weakness, fatigue,
sweats, chills, arthrarlgias, myalgias; Organ damage/ organopathy: hepatomegaly (H) H*: hepatomegalia with elevated alkaline phosphatase; spleno-
megaly (S); Adenopathy (A);Osteopenia/osteoporosis/osteolysis (O);iHES: idiopathic hypereosinophilic syndrome; MDS: myelodysplastic syndrome;
AML: acute myeloid leukaemia; ET: essential thrombocythaemia; MM: multiple myeloma; MF: myelofibrosis; PTCL: peripheral T-cell lymphoma;
CML: chronic myeloid leukaemia; B-ALL: B-cell acute lymphoblastic leukaemia; PV: polycythaemia vera
Table 2 The main characteristics indicating bone marrow biopsy, and the main results
Subgroups Main clinical symptoms /findings/features KIT mutation (PCR) D816V(+) BM dysplasia BM fibrosis BM eosinophilia
ISM urticaria, anaphylaxis,osteoporosis 11/14 1/14 0/14 6/14
SM-AHNMD cytopenias, splenomegaly, 12/15 5/15 3/15 3/15
ASM cytopenias, splenomegaly, eosinophilia 5/6 1/6 0/6 3/6
Abbreviations: ASM aggressive systemic mastocytosis; BM bone marrow; ISM: Indolent systemic mastocytosis; SM-AHNMD systemic mastocytosis
with an associated clonal hematologic non-mast cell lineage disease
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In the SM-AHNMD cases, it was predominantly the symp-
toms of the associated neoplasm that indicated the bone mar-
row biopsy. In the majority of our patients (14/15; 93%), these
were symptoms of pancytopenia, anaemia, leukocytosis,
thrombocytosis, bone pain/lesion or hepatosplenomegaly. In
one case, attention was drawn to the associated SM by the
lymphoma staging process. Our finding was consistent with
previous reports [16] whereas the most common associated
clonal diseases was myeloid neoplasms (12/15 cases; 80 %)
and the associated lymphoid neoplasms was much less com-
mon (3/15 cases; 20 %).
In the ASM subgroup, the bone marrow biopsy was indi-
cated in all cases (6/6; 100 %) by anaemia with or without
thrombocytopenia or hepatosplenomegaly with or without
constitutional symptoms.
It has been reported [9] that ISM is mostly associated with
cutaneous symptoms and this is in agreement with our own
findings (8/14 cases; 57 %), whereas we observed a lower rate
of these associations in ASM (2/6; 33 %), and there were no
such cases in SM-AHNMD.
Only the KIT D816V mutation was detected among our
cases, with a frequency close to the reported data [30]. This
mutation was positive in 78 % (11/14) of the ISM cases, 80 %
(12/15) of the SM-AHNMDcases, and 83% (5/6) of the ASM
patients.
Lim et al. concluded that the life expectancy in ISM was
superior to that in non-ISM, and not significantly different
from that for the age- and sex-matched US population, a result
that validated the prognostic relevance of the WHO subclas-
sification of SM [16]. A long-term study of the Spanish
Network on Mastocytosis also led to the finding that the great
majority of adult ISM patients have a normal life expectancy
[19]. Our analyses of Hungarian patients revealed that the
survival rate of SM patients is less than that expected for the
age- and sex-matched Hungarian population; The life expec-
tancy of the patients with ISMwas excellent, whereas the SM-
AHNMD and ASM groups exhibited a reduced median sur-
vival. This distribution of subtypes and survival pattern in our
study was similar to previously published in the Mayo clinic
study [17].
The recently established centralized ECNM registry cur-
rently collects data from ten European countries, and epide-
miological data are already therefore available as concerns the
prevalence of SM [8]. The prevalence of mastocytosis in
Central Europe has been estimated to be ~0.5–1/10,000 [5].
Our findings of the 13-year cumulative incidence of SM in
general population aged 15 years or more was 0.27/10,000 fit
the incidence of orphan diseases. As in the most relevant lit-
erature, we can not report a gender predominance [5].
Limitations
Since only cases that complied strictly with the WHO criteria
were included as SM cases, the cumulative incidence of SM
calculated during our research is likely to be somewhat
underestimated. On this basis, the 13-year cumulative inci-
dence of SM in our research was 0.27/10,000, and only the
clinical features of this group of patients were considered.
Only the SM cases were enrolled in our detailed investiga-
tion. Those patients with skin lesions, who refused the BM
biopsy, were not enrolled in our calculations.
The cumulative incidence would be increased by inclusion
of the patients (3) with only two minor criteria (whose data are
not included in the present manuscript), whose serum tryptase
Fig. 2 Survival of systemic
mastocytosis patients classified
by disease type. The observed
Kaplan-Meier survival for
systemic mastocytosis patients
classified by disease type: ISM
(blue), SM-AHNMD (green), and
ASM (yellow)
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examinations may later lead to some of them fulfilling the
three minor WHO criteria.
The real cumulative incidence might be higher because SM
is often underdiagnosed and the symptoms can be subtle or
absent.
Conclusion
This clinical overview clearly showed that the clinical charac-
teristics differ between ISM (UP, anaphylaxis and osteoporo-
sis) and SM-AHNMD/ASM (cytopenia, eosinophilia and
splenomegaly).
Despite the existence of the centralized ECNM registry and
the avaliability of some epidemiological data on the incidence
and prevalence of SM, the lack of an official national
mastocytosis registry in Hungary led us to apply our regional
data to calculate the cumulative incidence of SM in south-
eastern Hungary. This cumulative incidence of SM in adults
was lower compared to the epidemiologic data reported in the
literature due to in our analyses involved only those patients
who had bone marrow biopsy and histopathologically con-
firmed SM [6].
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